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Abstract With the rise in obesity epidemic primary hyper-
tension (PH) is now one of the most common chronic
diseases in adolescence. In contrast to hypertensive adults,
hypertensive children usually are not exposed to other
comorbidities such as diabetes, chronic kidney disease and
atherosclerosis. Thus, PH in children and adolescents can be
treated as the early stage of development of cardiovascular
disease. There is increasing amount of data indicating that
PH is not only hemodynamic phenomenon but a complex
syndrome involving disturbed activity of sympathetic ner-
vous system, metabolic abnormalities and activation of in-
nate and adaptive immune system. We discuss results of the
studies on clinical, metabolic and immunological phenotype
of hypertensive children, associations between metabolic
and immunological abnormalities with target organ damage
and results of antihypertensive treatment.
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Introduction
Cardiovascular disease (CVD) has its origin in childhood
and may be programmed perinatally [1]. One of the main
risk factors of CVD is primary hypertension (PH). With the
rise in obesity epidemic PH has become one of the most
common childhood diseases. The frequency of arterial hy-
pertension in 8-18 years-old children is about 2–3.6 % and
is almost 10 % among 18 years old adolescents [2].
Although clinically evident complications of PH do not
appear before the fourth to fifth decade of life, hypertensive
target organ damage (TOD) is evident already in hyperten-
sive children [3]. There is increasing amount of data indi-
cating that PH is not only a hemodynamic phenomenon, but
a complex disease involving sympathetic nervous system,
metabolism and immune system. Below, we discuss results
of the studies on clinical, metabolic and immunological
phenotype of hypertensive children, associations between
metabolic and immunological abnormalities with TOD and
results of antihypertensive treatment. Finally, hypotheses
linking immune and metabolic abnormalities with elevated
blood pressure are presented.
Clinical Phenotype of PH in Childhood
Blood pressure (BP) values in children strictly correlate with
biological development and body size. Therefore, assuming
that height and age are the main determinants of BP, refer-
ential BP values have been adjusted according to age and
height. However, obesity epidemic changed this relation-
ship. A population study on almost 18,000 randomly cho-
sen, healthy school age children clearly showed that body
mass but not height determined population BP. Moreover, it
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was waist circumference (WC), increased body mass and
lower height what were the main predictors of BP [4].
Relations between anthropometrical parameters and BP are
even more evident in children with PH. The typical inter-
mediary phenotype, overweight, obesity and increased body
mass index (BMI) may serve as the discriminating factors in
differential diagnosis of PH in adolescents [4–8]. More than
20 % of children with PH in the USA and Europe are obese
or overweight [4, 9] and analysis of body composition
showed that children with PH had higher fat mass and low
lean body mass/fat mass ratio in comparison with normo-
tensive children [7].
There are data indicating that maintenance of normal
BMI and body composition protects against BP rise. The
normotensive or prehypertensive adults in the mean age of
60 years who did not increase BMI and/or decreased BMI or
WC during the 5-year follow-up period, showed no increase
in their BP. Similarly, the fit subjects more often presented
normal blood pressure than the non-fit subjects [10••].
Similarly, the young men who increased theirs BMI during
the 10 years period had greater BP than those who
maintained normal weight [11].
Accelerated Rate of Biological Development
Based on the observations of Pickering’s group, Lever and
Harrap in 1992 proposed that PH is a disorder of growth
with origins in childhood [12••, 13]. According to it, hyper-
trophy of arterial wall smooth muscle cells and metabolic
changes, including insulin resistance (IR) may be at least in
part associated with accelerated biological maturation,
which together may lead to hypertension and CVD.
In 1980 Katz et al, described accelerated biological devel-
opment expressed as bone age in hypertensive children [14•].
In the study of hypertensive boys it was found that rate of
biological development expressed as the difference between
bone age and chronological age, was increased by 1.5 years in
comparison with age and BMI matched peers [15•]. In addi-
tion, there was linear relationship between acceleration of
bone growth with BP status from normotension, through
prehypertension, stage 1 to stage 2 hypertension. Growth
spurt, another marker of maturity (in Poland about 13.5 year
of age), was found to be strictly related with a significant rise
in BP values in boys but not in girls [16, 17•]. It fits well with
observation that the ratio of boys to girls among hypertensive
adolescents is 2–3: 1. These findings were confirmed in
retrospective study from Iceland. It was shown that adult
males who had the highest growth velocity between age
8 and 13, had 66 % increased risk of hypertension in compar-
ison with males who had lowest growth velocity [17•].
Similarly, in the prospective Young Finns Study woman
who had been younger at menarche were hypertensive, had
metabolic syndrome (MS) and were viscerally obese in fourth
decade of life [18•].
Biochemical Phenotype of Hypertensive Children
Childhood PH is characterized by biochemical phenotype
typical for metabolic abnormalities associated with visceral
obesity, such as hypertriglycerydemia, low HDL-cholesterol,
glucose intolerance and IR. It is estimated that prevalence of
MS equals 15 to 20 % among adolescents with PH and is 10
times more prevalent than in general adolescent population
[19].
The other typical metabolic abnormality found in chil-
dren with PH is tendency to greater concentrations of uric
acid. It was found that 89 % of children with PH had serum
uric acid concentrations above 5.5 mg/dl in comparison with
30 % of children with secondary hypertension and none
with white coat hypertension and normotensive controls
[20•]. Moreover, treatment with allopurinol or probenecid
caused not only decrease of serum uric acid concentrations
but also was associated with blood pressure decrease in
obese, stage 1 hypertensive and prehypertensive children
[21, 22•].
Increased oxidative stress (SOX) has been described in
adults with PH, but there are only few data from pediatric
studies on SOX in PH [23, 24•]. It was found that the hyper-
tensive children had decreased levels of antioxidative defense
system and elevated concentrations of reactive oxygen species
(ROS). In the prospective study of 86 PH children, those with
severe ambulatory hypertension had lower concentrations of
glutathion than children with ambulatory hypertension [24•].
Furthermore, hypertensive children with MS had lower activity
of glutathione peroxidase, higher serum concentrations of asym-
metric dimethylarginine (ADMA) and oxidized LDL-cholesterol
(oxyLDL) than hypertensive children without MS. SOX was
also associated with left ventricular hypertrophy.
Immunological Characteristics of Hypertensive
Children
There is a significant graded relationship between BP and
serum sICAM-l and IL-6 concentrations indicating that in-
creased BP is correlated and/or may stimulate systemic low-
grade inflammation [25]. Chronic subclinical inflammation is
considered as a part of the MS [26]. Moreover, inflammatory
markers predict the development of diabetes and of IR [27].
The sub-acute inflammation leading to vascular inflammation
and hypertension can be activated by: (1) ongoing intra-
arterial inflammation mediated by wall-resident macrophages
which respond to various endogenous inducers, (2) low-level
extravascular stimuli as smoking, aging, obesity, mucosal or
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oral infections such as bronchiltis, gastritis, or periodontitis,
and (c) the hemodynamic insult caused by elevated blood
pressure and pulse pressure. The resulting inflammatory re-
sponses are associated with IR and play role in pathogenesis
of CVD [28].
Analysis of the immune profile of hypertensive adults was
estimated on the basis of serum level concentration of many
inflammatory mediators such as acute phase proteins (like
CRP), cytokines, chemokines, metalloproteinases (MMP),
collagen degradation products, oxidative stress markers,
adipokines, including leptin, adiponectin, resistin, etc. The
results confirmed that PH is associated with ongoing systemic
inflammation. This approach however has some limitations.
Most inflammatory mediators act as autocrine/paracrine fac-
tors, so their circulating levels may not reflect their patho-
physiological roles. It is also difficult to indicate if changes in
their serum levels are primary or secondary to the ongoing
inflammatory process. This concerns especially the adult hy-
pertensive patients who are often exposed to many con-
founders such as smoking, drugs, diet customs, etc. In study
including only children with PH we found that hypertensive
children had greater serum concentrations of highly sensitive
C reactive protein (hsCRP) and chemokines (RANTES,
MIP1β) in comparison with normotensive children. hsCRP
levels correlated with MS, visceral obesity, SOX and markers
of TOD such as increased carotid intima-media thickness
(cIMT) and left ventricular mass. RANTES levels correlated
with dyslipidemia. Elevated hsCRP levels did not correlate
neither with RANTES nor MIP1β. RANTES acts mainly as a
memory T cell attractant, but MIP-1 β is responsible for
monocyte attraction to the inflammation site. Therefore lack
of correlation between their levels and systemic inflammation
marker such as hsCRP may suggest that vascular inflamma-
tion somehow precedes systemic inflammatory events [29].
These results indicate that systemic immune activation already
occurs in the early stage of PH.
Activation of both innate and adaptive immune system has
been shown to play role in pathogenesis of PH in experimental
models and in humans [rev. in 30, 31••]. Cells of the immune
system, including peripheral blood leucocytes (PBL) contain
full enzymatic machinery of renin-angiotensin system (RAS),
the central player in circulatory homeostasis [32, 33].
Moreover, angiotensin 2 (AT2) and angiotensin receptor
blockers (ARB) modulate reciprocally function of both innate
and adaptive immune system [33, 34]. Chon et al. analyzed
genes expression in leukocytes of six untreated and six treated
hypertensive adults and found that in untreated patients expres-
sion of 680 genes was altered, of which 314 were upregulated
and 366 were dow-regulated. On the contrary, in treated pa-
tients, who had significantly lower BP, only four genes were
up-regulated and three were down-regulated. Among up-
regulated genes were those involved in inflammatory reaction,
antioxidative defense and RAS. Furthermore, normalization of
BP corrected these changes [35]. Coppo et al. found in PBL
from hypertensive adults upregulated expression of 21 genes
known to be engaged in apoptosis, inflammatory responses,
vesicular trafficking of molecules among cellular organelles,
and other processes [36]. In yet another study, the expression
pattern of the majority of genes was similar regardless the
disease stage and antihypertensive therapy [37]. In pediatric
study, PBL from untreated children with PH had increased
expression of mRNA of ACE and CD14. Angiotensinogen
(AGT) and AT2 type 1 receptor (AT2R1) mRNAs expression
were down regulated. Moreover, children with increased cIMT
had significantly lower renin (REN) mRNA expression [38].
The reason for that is not clear, but strongly suggests that RAS
system in PBL must be activated early in the course of PH.
These reports confirm and extend the idea that PH is
associated with complex inflammatory responses which en-
gage many genes involved both in immune system activation
and BP regulation. The changes in their expression can be
found in PBL so it makes possible to eventually classify the
disease, its clinical course and responsiveness to treatment.
These studies also indicate that leukocytes may serve as
“sensors” of PH. However, results of above mentioned studies
do not indicate which cells of immune system initiate the
inflammatory cascade resulting in hypertension. It is known
from experimental studies with genetically modified mouse,
that hypertension is associated with T cells and macrophages.
According to hypothesis proposed by Harrison et al. these
cells infiltrate kidney and vasculature which are crucial for BP
control [31••]. According to this hypothesis, modest BP ele-
vation results in activation of endothelium. Activated endo-
thelium reveals neoantigens which are taken up by dendritic
cells and present them to T cells recognizing them as non-self
in the regional lymph nodes. Non-self recognition induces
strong T cells activation, proliferation and differentiation. In
the prehypertension stage, the pool of sensitized T cells is
relatively small but their numbers increase with subject age
so does inflammation. The most important subset of T cells
engaged in inflammatory reaction and elevation of BP is Th17
T cell subset. Th17 produce IL-17 and are engaged in many
autoimmune diseases including rheumatoid arthritis, inflam-
matory bowel disease, psoriasis, sclerosis multiplex, SLE, etc.
IL-17 exerts its effect by production of chemokines and ad-
hesionmolecules in tissue. This leads to accumulation of other
inflammatory cells in the vascular wall (kidney, peripheral
vessel wall), promotes ROS production in the vascular smooth
muscle cells and decreases nitric oxide synthesis by endothe-
lial cells. It causes vasoconstriction, sodium retention and
hypertension [39]. It was found that mice lacking T-
lymphocytes and B lymphocytes are resistant to development
of both angiotensin II, DOCA-salt, epinephrine, or stress-
induced hypertension. On the contrary, adoptive transfer of
T cells, but not of B lymphocytes, restored hypertensive
response to these stimuli [40••, 41].
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Inflammation is controlled by T-regulatory cells (T-regs)
which limit the extent of the response and prevents the tissue
damage (in this case arteriolar wall causing hypertension).
T-regs can stop inflammation by acting on T cells, B cells,
macrophages, dendritic cells and NK lymphocytes. In the
mouse model, adoptive transfer of T-regs limited hyperten-
sion and organ damage induced either by AT2 or aldosteron
[42••]. These results indicate that T-regs can be generated in
the course of hypertension at least in the experimental
models with use of stimuli such as high salt feeding, AT2,
and aldosterone. In our yet unpublished study of untreated
children with PH, we found that PBL from hypertensive
children responded more vigorously (as assessed by cyto-
kines expression profiles) to T cell stimuli such as
lipopolysacharide, than PBL from normotensive children
with non-alcoholic fatty liver disease and from healthy
children. In addition, CD4 from children with PH had in-
creased T-regs and Th17 cell population in comparison with
normotensive, age and BMI matched children. Additionally,
the number of Th17 cells was greater in those patients
whose leukocytes did not express adiponectin type 1 re-
ceptors (AdipoR1) (unpublished results). This indicates that
decreased AdipoR1 expression may limit leukocyte respon-
siveness to adiponectin. This in turn may increase synthesis
of proinflammatory IL-17 by T cells (Fig. 1). These obser-
vations are an argument for significance of adipose tissue
and adipokines in the regulation of the inflammatory re-
sponses in hypertensive children.
Signals which lead to differentiation of naive CD4+ T
cells into proinflammatory Th17 cells require IL-6 and
TGF-beta. In contrast, T-regs need TGF-beta—an anti-
inflammatory cytokine produced mainly by macrophages
and monocytes—for their differentiation from naïve CD4+
T cells and synthesis of FOXP-3 by T-regs. In contrast, IL-
6—a ubiquitous and multifunctional cytokine which can be
produced by many cell types, including T and B cells,
fibroblasts, endothelial cells, macrophages, adipose tissue
macrophages, monocytes, and dendritic cells—is a high
inducer of acute phase response and its serum concentra-
tions correlate with BP in healthy subjects.
There is strictly controlled relation between T-regs and
Th17 cells. In the presence of TGF-beta but of low IL-6
concentrations, naive T cells preferentially polarize into T-
regs, and Th17 cells may transit into T-regs. However, when
cytokines milieu contains mainly pro-inflammatory cytokines
such as IL-6 and low TGF-beta concentrations, then T cells
preferentially polarize into Th17, and T-regs may lose FOXP-
3 expression and transit into Th17 cells. It suggests that type of
inflammatory reactions generated during initial phases of re-
sponses to vascular antigens may decide about the immune
response profile. According to this scenario it was de-
scribed recently that IL-6 accumulates in the kidney, es-
pecially the glomeruli, of patients with chronic kidney
disease and hypertension, to a greater extent than in nor-
motensive patients with CKD [43].
RAS in immune cells may be an autonomous source of
AT2 independently of circulating and tissue RAS [44].
Proinflammatory signals may increase immune system cells
sensitivity to AT2. For example, T cells of hypertensive
adult patients showed no changes in baseline mRNAs ex-
pression for angiotensin converting enzyme (ACE) and
AT2R1 but stimulation with angiotensin II resulted in rapid
increase in both ACE and AT2R1 expression. Systemic
inflammation expressed as increase in serum CRP level,
correlated with T cells response to AT2, indicating that
AT2–driven T cell RAS was further up-regulated by low-
grade inflammation [36].
The consequence of immune activation and hemodynam-
ic injury is extracellular remodeling and fibrosis. The main
controlling system of extracellular matrix remodeling is
system of matrix metalloproteinases (MMP) and its tissue
inhibitors (TIMP). The results of recently published meta-
analysis indicate that both concentrations and activities of
MMP-9 and TIMP-1 are disturbed in adults with hyperten-
sion and correlate with left ventricular hypertrophy [45•]. It
was also found that serum adiponectin concentrations cor-
relate negatively with MMP-9 and TIMP-1, and MMP-
9/TIMP-1 ratio is a predictor of stability of coronary athero-
sclerotic plaque and extent of coronary atherosclerosis [46].
Pediatric reports refer to children with obesity, diabetes or
MS [47]. It was found that obese and hypertensive children
had greater concentrations of MMP-9 than obese, normo-
tensive children. Moreover, both MMP-9 and TIMP-1 cor-
related with BMI, systolic blood pressure and IR. In our
study we found that hypertensive children have greater
concentrations of MMP-9 in PBL and in serum in compar-
ison with age and BMI matched normotensive children [48].
Moreover, hypertensive children with MS had greater con-
centrations of TIMP1 in comparison with hypertensive chil-
dren without MS.
Target Organ Damage in Children with Primary
Hypertension
Both left ventricular mass index (LVMI), carotid intima-
media thickness (cIMT) and arterial stiffness increase with
change of BP status from normotension, through
prehypertension to hypertension and correlate with severity
of hypertension [49, 50]. The same was observed in children
with normotension, white coat hypertension, and hyperten-
sion [51]. However, change of BP status was also accom-
panied by increasing adiposity and metabolic abnormalities.
In studies of children with PH it was repeatedly shown that
already at diagnosis left ventricular hypertrophy (LVH)
expressed as LVMI above 95th percentile for age and sex,
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was present in 38–46 %, and severe LVH expressed as
LVMI above 52 g/m height2.7 was found in 13–15 % [3,
52, 53•]. Prevalence of LVH was greater in children with
severe ambulatory hypertension in comparison with chil-
dren who had ambulatory hypertension, and the most prev-
alent form of LVH in hypertensive children was eccentric
Fig. 1 Relationship between adiponectin receptor type 1 (AdipoR1)
expression levels in neutrophils and numbers of IL-17 expressing CD4
T cells (Th17+) and CD4+ T regs cells bearing CD4+ /CD25high/
CD127low phenotype. Flow cytometry analysis of peripheral blood
(PB) cells gated as neutrophils (AdipoR1 expression, left column)
and CD4+ T cells bearing Th17 or T-regs phenotype (middle and right
column, respectively). The plots are representatives for 25 controls and
23 PH children. Results: 1) low numbers of Th17 and T-regs in control
positive for neutrophil AdiopoR1 expression, 2) high expression of IL-
17 and T-regs cells in PH children negative for neutrophil AdipoR1
expression, 3) low IL-17 expression (like in the control) in PH children
bearing neutrophil AdipoR1, 4) increased T-regs numbers in PH chil-
dren as compared to controls. Abbreviations: AdipoR1 – adiponectin
receptor type 1; IL-17 – interleukin 17; PH – primary hypertension; T-
regs – T regulatory cells
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hypertrophy [50, 52, 53•, 54, 55]. Extent and severity of
TOD correlated with visceral obesity and metabolic abnor-
malities and it was found that prevalence of LVH increased
with exposure to increasing number of MS criteria [19].
Moreover, severe LVH was found only among patients
who had MS. Similarly, about 40 % of children with PH
had signs of hypertensive arteriopathy expressed as in-
creased cIMT [9, 53•]. Metabolic abnormalities, especially
atherogenic dyslipidemia, aggravate arterial wall injury
caused by elevated BP. In analysis of group of children with
PH, increased cIMTwas predicted by pulse pressure, homo-
cysteine concentrations, low HDL cholesterol levels,
adiponectin, hsCRP, angiogenin and WC [9, 19, 29, 52,
53•]. Similarly, concentrations of thiobarbituric acid
substances—a marker of SOX—correlated with LVMI, con-
centric LVH, cIMT and albuminuria [24•].
Effects of Treatment of Primary Hypertension
in Children and Adolescents
According to recent guidelines, treatment of PH in children
and adolescents should start with nonpharmacological treat-
ment and include both dietary changes and increased physical
activity [56, 57•]. Pharmacological treatment should be added
for patients with stage 2 hypertension and/or TOD. Due to
typical intermediate phenotype and associated metabolic ab-
normalities with special emphasis on IR, the best pharmaco-
logical treatment option is use of angiotensin converting en-
zyme inhibitors (ACEi) or ARB. Although results of clinical
trials documented that both ACEi and ARBs are effective and
safe as antihypertensive drugs in children, these studies in-
cluded patients mainly with secondary forms of hypertension
[58, 59].
There are only few prospective studies evaluating effects
of treatment specifically in children with PH. In our reports
we analyzed results of both non-pharmacological and phar-
macological treatment based on ACEi or ARB in children
with PH [24•, 53•]. The principles of treatment were as
follows: pharmacological treatment was started in pts who
had significant TOD and/or severe ambulatory hyperten-
sion. If after 3 or 6 months office BP was still in the
hypertensive range, ambulatory blood pressure monitoring
(ABPM) was done. In pts who still had ambulatory or severe
ambulatory hypertension, pharmacotherapy was started or
another drug was given. Drug therapy was based on an
ACEi (enalapril 0.2–0.3 mg/kg/day bid), and in patients
who had asthma or did not tolerate ACEi, losartan (0.–
1 mg/kg/day in one or two daily doses) was prescribed.
Amlodipine was used as second drug. After one year
normotension has been achieved in 70 % of pts, including
60 % in optimal BP range and 10 % in prehypertensive
range. It was accompanied by significant regression of TOD
expressed as LVH and increased cIMT, decrease of MS
prevalence by 50 % and decrease of inflammatory activity.
However, concentric LVH was less prone to decrease.
Moreover, despite significant lowering of BP the main pre-
dictor of TOD regression was not decrease of BP but de-
crease of visceral obesity expressed as decrease of WC and
decrease of IR [53•, 54]. Treatment caused also significant
decrease of SOX (23). Another prospective study of effects
of 6 months of non-pharmacological treatment in 23 adoles-
cents with stage 1 PH, revealed significant changes in genes
expression in peripheral blood leucocytes. There was sig-
nificant decrease of expression of genes of AT2R1, AGT
and ACE. CD40 molecule expression decreased but non-
significantly [38].
Observation of BP rhythms in ABPM before and after
one year of antihypertensive treatment in 50 adolescent boys
with PH gave interesting results. After 1 year of treatment,
68 % of patients were normotensive, and left ventricular
mass and cIMT decreased in 60 % and 62 % of patients
respectively. However, on average, BP and heart rate pat-
terns did not change. More detailed analysis revealed that
changes in BP amplitude correlated with the decrease of WC
(p=0.035). Moreover, the decrease of visceral fat amount
assessed by magnetic resonance, correlated with the de-
crease of 24-h mean arterial pressure and heart rate
acrophases (both p<0.05). There were no differences in
changes of BP/heart rate rhythms between patients who
achieved or did not achieve normotension and/or regression
of LVMi and cIMT [60]. Persistence of abnormal cardio-
vascular rhythmicity in children with PH despite effective
antihypertensive treatment suggests that it may be the pri-
mary abnormality. However, the correlation between
changes in cardiovascular rhythmicity and visceral obesity
may indicate that the visceral fat plays an important role in
the sympathetic activity of hypertensive adolescents.
Fig. 2 Schematic classification of arterial hypertension in children and
adolescents. Abbreviations: BMI – body mass index; WC – waist
circumference
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Conclusions
Described above clinical, immuno-metabolic and hemody-
namic phenotype of children with PH and determinants of
treatment efficacy are in line with paradigm describing PH in
children and adolescents as immuno-metabolic disease strictly
linked to visceral obesity and disturbed body composition.
There is significant relationship both between body growth,
body composition, fat tissue distribution, immune and meta-
bolic abnormalities with PH, disturbed cardiovascular
rhythms and hypertensive TOD. According to this, we pro-
pose classification of childhood hypertension as depicted on
Fig. 2. In this scheme, PH can be further divided on the basis
of not only of fat amount but also of fat tissue distribution.
Thus PH in children can be divided into PH in children with
elevated and normal BMI but with increased visceral adipos-
ity. PH in children and adolescents with normal body compo-
sition and without metabolic abnormalities seems to be dis-
tinct entity, including cases of so known spurious hyperten-
sion [61•] Accordingly, basing on findings both from cross-
sectional and prospective studies, we hypothesize that it is
normalization of immuno-metabolic abnormalities and body
composition what determines normalization of both TOD and
cardiovascular rhythmicity. Such a view considers elevation
of BP in childhood as the first step in development of CVD.
Usually typical clinical phenotype is accompanied by subtle
immuno-metabolic abnormalities. In this stage of disease both
metabolic and hemodynamic abnormalities and TOD are usu-
ally reversible and regression of TOD correlates with normal-
ization of immune activity. However, some forms of LVH
(concentric hypertrophy) are less prone to treatment. It is
assumed that the next stage of disease, clinically evident in
adulthood evolves into the third stage of irreversible cardiac,
renal and vascular changes [31••]. The evolution of hyperten-
sive disease is accompanied by evolving pattern of sodium
sensitivity from renin-dependent hypertension to sodium de-
pendent hypertension [62••].
There are still unresolved problems. There are no data
linking pathogenically immune and metabolic abnormalities
with disturbed cardiovascular rhythms. However, there are
some hypotheses linking central autonomic activity with im-
mune phenomena in hypertensive animals [63•]. The primacy
of increased central autonomic activity or secondary to visceral
adiposity and metabolic abnormalities is also unresolved.
Secondly, there are no data if normalization of BP, body com-
position and immuno-metabolic abnormalities allows to dis-
continue antihypertensive treatment. It seems that even if it is
possible, those subjects could be prone to develop hypertensive
disease later in life. Increasing amount of data indicate that both
primary prevention and antihypertensive treatment of children
and adolescents with PH should be aimed to immune-
metabolic abnormalities and disturbed body composition and
not only to blood pressure lowering. However, this hypothesis
should be proven in multicenter prospective trials, examining
effects of different drug classes not only in terms of decrease of
blood pressure but also analyzing regression of target organ
damage and metabolic abnormalities.
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